When 69-year-old Maria Schmidt limped into the radiology suite at Charité-Universitätsmedizin Berlin, she had tried everything—physical therapy, painkillers, steroid injections—but nothing stopped the grinding ache in her knees. Then came a 90-minute procedure with no surgery, no implants, and no general anesthesia. Six months later, she was walking without a cane for the first time in five years. Her story is one of 194 captured in a groundbreaking study that could reshape how we treat knee osteoarthritis, a condition affecting over 365 million people worldwide.
For patients caught in the treatment gap—too far beyond conservative care but not ready or eligible for joint replacement—genicular artery embolization (GAE) is emerging as a beacon of hope. Led by Dr. Florian Nima Fleckenstein, a team at Charité-Universitätsmedizin Berlin tested a refined version of GAE using rapidly resorbable, gelatin-based microspheres, tiny particles that dissolve within hours yet deliver lasting effects. These microspheres are injected via catheter into abnormal blood vessels around the knee—vessels that, in osteoarthritis, become overgrown and fuel chronic inflammation and pain.
The study, published in Radiology, followed 194 patients—114 women and 80 men—with a median age of 69, all of whom had failed at least three months of standard treatment. Between July and November 2024, they underwent a total of 239 GAE procedures, with 45 patients receiving treatment in both knees. Every procedure was technically successful, and follow-up rates remained high: 94% at six weeks, 89% at three and six months, and 85% at one year. Most strikingly, 6.7% of patients reported only mild, short-lived side effects—no moderate or severe adverse events were recorded.
Pain scores, measured on a 0–10 scale, dropped from a median of 7.5 before treatment to 3.1 at six months and 3.3 at one year. Equally important, patients reported significant improvements in mobility and daily function. "GAE with resorbable microspheres may be the first procedure that alters the course of the disease, slowing its progression," Fleckenstein said. This isn’t just symptom relief—it’s a potential shift in disease trajectory.
While joint replacement remains the gold standard for end-stage arthritis, GAE offers a compelling alternative for earlier intervention. With no implants, minimal recovery time, and strong safety data, it could soon become a routine option in orthopedic and interventional radiology clinics worldwide. For millions living with the daily grind of knee pain, the future may not require a scalpel—just a catheter, and a new way of thinking about inflammation.